Idorsia partners with Jamjoom Pharma to roll out insomnia drug QUVIVIQ in Saudi Arabia and the Levant
Executive summary: Idorsia signed an exclusive partnership with Jamjoom Pharma to commercialize and distribute its insomnia medication QUVIVIQ (daridorexant) in Saudi Arabia and the Levant. The agreement opens a new Middle‑East market for Idorsia’s flagship sleep disorder therapy, potentially boosting revenue and strengthening Jamjoom Pharma’s product lineup.
Who is involved: Idorsia (Swiss biotech), Jamjoom Pharma (regional pharmaceutical distributor), and the drug QUVIVIQ (daridorexant); the territories covered are Saudi Arabia and the Levant.
Likely next: Jamjoom Pharma will begin distributor training and launch activities in Q4 2026, with Idorsia evaluating similar partnerships in other Gulf states and preparing regulatory submissions for any required local authorizations.
Idorsia announced an exclusive agreement with Jamjoom Pharma to commercialize and distribute QUVIVIQ (daridorexant) in Saudi Arabia and the Levant. The deal grants Jamjoom Pharma rights to market the drug, which is already approved for insomnia in several markets. This move expands Idorsia’s geographic footprint in a high‑growth pharmaceutical region and provides Jamjoom with a differentiated product for its portfolio.
Timeline
- — Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant (GlobeNewswire)
Analysis — what this means
Likely next events
- Jamjoom Pharma to initiate distributor training for QUVIVIQ in Saudi Arabia by September 2026
- First commercial launch of QUVIVIQ in the Levant expected Q4 2026
- Idorsia to explore additional Middle‑East partnerships in UAE and Qatar by early 2027
- Regulatory review of daridorexant labeling with Saudi FDA anticipated Q3 2026
Sectors affected
- insomnia therapeutics
- Middle East pharmaceutical distribution
- Saudi Arabia healthcare market